Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
1.
Vestn Ross Akad Med Nauk ; (3): 355-9, 2015.
Artículo en Ruso | MEDLINE | ID: mdl-26495725

RESUMEN

OBJECTIVE: The aim of our study was to compare the changes in the severity of positive, negative and psychopathological PANSS symptoms which occur at an outcome of an attack in schizophrenic patients along with remission formation and the degree of platelet activation in these patients. METHODS: Psychometric scale of the Positive and Negative Syndrome Scale (PA NSS) and the method of estimation of platelet activation based on the calculation of cells number after elution from the column with sepharose CL-2B were used. RESULTS: The changes in the severity of the disease were estimated using the PANSS scale of chronic schizophrenic patients in remission formation. An increase in platelet activation was determined on the basis of the above described quantitative parameter. Comparison of changes in platelet activation parameter with changes in the disease severity rating detected similar statistically indistinguishable (p > 0.05) changes in the severity of positive symptoms and quantitative variable of platelet activation between the 1st and the 3rd visits in the period of remission formation. Platelet number after elution from the column during the 3rd visit was approximately two times less than during the 1st visit (p < 0.002). PANSS positive subscale shows a decrease of the severity of the syndrome by 1.6 times (p < 0.0002). In addition the difference between the platelet activation parameter and severity of the negative syndrome was fixed during the 3rd visit (p < 0.034). CONCLUSION: Similar changes in the severity of positive syndrome and platelet activation parameter were presented from 1st to 3rd visit in the remission formation. A distinction between the platelet activation parameter and severity of the negative syndrome was fixed during the 3rd visit.


Asunto(s)
Síntomas Conductuales , Activación Plaquetaria/efectos de los fármacos , Risperidona/farmacología , Esquizofrenia , Adulto , Antipsicóticos/farmacología , Síntomas Conductuales/sangre , Síntomas Conductuales/diagnóstico , Estudios de Cohortes , Humanos , Masculino , Persona de Mediana Edad , Moscú , Gravedad del Paciente , Estudios Prospectivos , Escalas de Valoración Psiquiátrica , Psicometría/métodos , Psicopatología , Inducción de Remisión/métodos , Esquizofrenia/sangre , Esquizofrenia/diagnóstico , Esquizofrenia/terapia , Psicología del Esquizofrénico , Índice de Severidad de la Enfermedad , Estadística como Asunto
2.
Vestn Ross Akad Med Nauk ; (9): 42-5, 2013.
Artículo en Ruso | MEDLINE | ID: mdl-24624872

RESUMEN

The purpose of this work was to evaluate the degree of activation of platelets chronically schizophrenic patients with paroxysmal course of the disease during outcome from the attack of disease or in process of forming of the remission. Platelets in platelet-rich-plasma (PRP) and after PRP gel-filtration through the column with Sepharose CL-2B taken from the ulnar vein of males with chronic schizophrenia during outcome from the attack of disease or in process of forming of the remission were measured. Patients were investigated on the peak of the disease attack (visit 1), at the stage of significant improvement of clinical state (visit 2), and at the stage of stable drug-induced remission (visit 3). Platelet quantities in PRP prepared by centrifugation are equal in patients in visits 1, 2 or 3. These platelets quantities are much less than similar platelet quantities in healthy individuals matched in age. The additional decreases of platelet quantities were found after the elution of PRP platelets from the column with Sepharose CL-2B. These additional platelet quantity losses are increased from visit 1 to visit 3. Such losses of cells indicate decrease in their resistance to various influences, their activation in spite of remission development in this group of patients.


Asunto(s)
Plaquetas/fisiología , Activación Plaquetaria/fisiología , Esquizofrenia/sangre , Adulto , Estudios de Seguimiento , Humanos , Masculino , Recuento de Plaquetas , Pronóstico
3.
Biol Psychiatry ; 25(4): 375-81, 1989 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-2930807

RESUMEN

In a population of drug-free bipolar and unipolar depressed women, it was found that the concentration of serotonin sufficient to induce half-maximal shape change velocity in platelets is significantly (p less than 0.001) lower (0.13 +/- 0.0.04 microM) than that of closely matched controls (0.532 +/- 0.1 microM). This platelet concentration becomes higher after 1-3 months of antidepressant treatment (0.47 +/- 0.16 microM). Possible mechanisms for this up- or down-regulation of platelet serotonin receptor responsiveness are discussed.


Asunto(s)
Antidepresivos/uso terapéutico , Trastorno Bipolar/tratamiento farmacológico , Plaquetas/efectos de los fármacos , Trastorno Depresivo/tratamiento farmacológico , Receptores de Serotonina/efectos de los fármacos , Serotonina/sangre , Adulto , Trastorno Bipolar/sangre , Carbazoles/uso terapéutico , Trastorno Depresivo/sangre , Femenino , Humanos , Imipramina/uso terapéutico , Masculino , Maprotilina/uso terapéutico , Persona de Mediana Edad , Agregación Plaquetaria/efectos de los fármacos
4.
Neurosci Lett ; 52(3): 259-62, 1984 Dec 21.
Artículo en Inglés | MEDLINE | ID: mdl-6521970

RESUMEN

The reversible specific binding of [3H]diazepam was observed by a radioligand method in homogenates of cultured cells of mouse glioblastoma. It was characterized by an equilibrium dissociation constant Kd = 91 +/- 5 nM and the number of maximal binding sites (Bmax) of 1006 +/- 100 fmol/mg protein. The half-saturation and half-degradation periods for the ligand-receptor complex were 15 and 10 s, respectively. The specific binding sites from glioblastoma are similar to the peripheral-type receptors as their inhibition constant for Ro 5-4864 Ki = 16 nM and that for clonazepam Ki = 30 microM.


Asunto(s)
Benzodiazepinonas/farmacología , Clonazepam/farmacología , Diazepam/metabolismo , Neuroglía/metabolismo , Animales , Sitios de Unión , Línea Celular , Glioma , Ratones
5.
Vestn Ross Akad Med Nauk ; (4): 29-32, 1996.
Artículo en Ruso | MEDLINE | ID: mdl-8754076

RESUMEN

The platelet parameters of the functional status of the serotonin-reuptake complex were studied in drug-resistant depressive patients given various regimens of complex therapy or selective serotonin re-uptake inhibitors (fluvoxamine and fluoxetine). The most persistent and marked clinical effect was seen in electroconvulsive therapy and it was due to the normalization of the serotonin-reuptake system.


Asunto(s)
Plaquetas/metabolismo , Trastorno Depresivo/sangre , Serotonina/sangre , Adulto , Transporte Biológico , Trastorno Bipolar/sangre , Trastorno Bipolar/terapia , Terapia Combinada , Trastorno Depresivo/terapia , Resistencia a Medicamentos , Terapia Electroconvulsiva , Femenino , Humanos , Masculino , Esquizofrenia/sangre , Esquizofrenia/terapia
6.
Vestn Ross Akad Med Nauk ; (7): 37-42, 2001.
Artículo en Ruso | MEDLINE | ID: mdl-11523428

RESUMEN

Polyclonal (PAb) and monoclonal (MAb) antibodies to CT2-epitope of the C-terminal fragment of serotonin transporter (SERT) protein were used to study the levels and molecular heterogeneity of platelet SERT in healthy donors and patients with affective (AD) and somatoform (SD) disorders, schizoaffective disorder (SAD) and schizophrenia. SERT was found to exist as high molecular wight (HMW) and low molecular weight (LMW) forms separated after electrophoresis. The levels of HMW and LMW forms of SERT were significantly, decreased in mentally ill patients as compared to healthy individuals. Unlike PAb, horse radish peroxidase (HRP)-conjugated MAbs were more sensitive and specific to SERT and could detect the LMW form of SERT as a duplet protein form with MW about 40 and 43 kDa. The MAb to CT2 C-terminal fragment of SERT conjugated with HRP is considered to be a new valuable tool for further investigation of SERT expression, properties, and posttranslation modification in the controls and in patients with different psychopathology.


Asunto(s)
Plaquetas/metabolismo , Proteínas Portadoras/sangre , Glicoproteínas de Membrana/sangre , Proteínas de Transporte de Membrana , Trastornos Mentales/metabolismo , Proteínas del Tejido Nervioso , Serotonina/metabolismo , Adulto , Animales , Anticuerpos Monoclonales , Proteínas Portadoras/genética , Proteínas Portadoras/metabolismo , Electroforesis , Epítopos , Femenino , Heterogeneidad Genética , Humanos , Técnicas para Inmunoenzimas , Masculino , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/metabolismo , Trastornos Mentales/sangre , Trastornos Mentales/genética , Ratones , Persona de Mediana Edad , Peso Molecular , Trastornos del Humor/sangre , Trastornos del Humor/genética , Trastornos del Humor/metabolismo , Transporte de Proteínas , Esquizofrenia/sangre , Esquizofrenia/genética , Esquizofrenia/metabolismo , Sensibilidad y Especificidad , Proteínas de Transporte de Serotonina en la Membrana Plasmática , Trastornos Somatomorfos/sangre , Trastornos Somatomorfos/genética , Trastornos Somatomorfos/metabolismo
7.
Artículo en Ruso | MEDLINE | ID: mdl-2960110

RESUMEN

Specific binding of 3H-domperidone was detected in a homogenate of human caudate nucleus tissue obtained from mentally healthy people and schizophrenic patients postmortem. Analysis of Scatchard's graph revealed only one type of binding sites with a dissociation constant of about 17 nM and the maximal number of binding sites about 87 pmol/g of the initial tissue. According to the current concepts, 3H-domperidone is a selective ligand of D2 dopamine receptors mediating the psychotropic effect of neuroleptics. The use of human brain for the investigation of these receptors may contribute to the elucidation of the mechanism of action of psychotropic drugs.


Asunto(s)
Núcleo Caudado/metabolismo , Domperidona/metabolismo , Receptores Dopaminérgicos/metabolismo , Anciano , Domperidona/análisis , Relación Dosis-Respuesta a Droga , Humanos , Ligandos , Persona de Mediana Edad , Ensayo de Unión Radioligante , Receptores Dopaminérgicos/análisis , Receptores de Dopamina D2 , Esquizofrenia/metabolismo , Tritio
8.
Artículo en Ruso | MEDLINE | ID: mdl-2633575

RESUMEN

Effective 5-HT concentration eliciting the half-maximal rate of platelet deformation (aggregation) in drug-free bipolar or unipolar depressed women was significantly (p less than 0.001) lower as compared with matched controls (0.13 +/- 0.04 microM and 0.532 +/- 0.1 microM, respectively). After 1-3 months of antidepressant treatment this value increased to 0.47 +/- 0.16 microM and was no longer different from control. Possible mechanisms controlling the activity of serotonin2 platelet receptors are discussed.


Asunto(s)
Antidepresivos/uso terapéutico , Plaquetas/análisis , Trastorno Depresivo/tratamiento farmacológico , Receptores de Serotonina/análisis , Serotonina/sangre , Adolescente , Adulto , Antidepresivos/administración & dosificación , Antidepresivos/farmacología , Trastorno Depresivo/sangre , Trastorno Depresivo/fisiopatología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Modelos Biológicos , Agregación Plaquetaria , Receptores de Serotonina/fisiología , Factores de Tiempo
9.
Artículo en Ruso | MEDLINE | ID: mdl-3232463

RESUMEN

The inhibitory effect of imipramine (IC50) on [3H]serotonin uptake and its kinetic parameter (V400) were measured in platelets of 9 patients with unipolar and 6 with bipolar affective disorder. The IC50 and V400 values in depressed patients were significantly higher (p less than 0.002) than these found in the control group. Treatment with antidepressants significantly decreased the IC50 values. The results support the hypothesis postulating that depression is related to a decreased modulatory capacity of imipramine binding sites and that the clinical effectiveness of these drugs is associated with the said modulatory capacity.


Asunto(s)
Trastorno Bipolar/tratamiento farmacológico , Plaquetas/metabolismo , Trastorno Depresivo/tratamiento farmacológico , Imipramina/uso terapéutico , Serotonina/sangre , Adolescente , Adulto , Trastorno Bipolar/sangre , Plaquetas/efectos de los fármacos , Medios de Cultivo , Trastorno Depresivo/sangre , Resistencia a Medicamentos , Femenino , Humanos , Imipramina/farmacología , Técnicas In Vitro , Persona de Mediana Edad , Antagonistas de la Serotonina
10.
Artículo en Ruso | MEDLINE | ID: mdl-2728713

RESUMEN

The potency of imipramine (IMI) and trazodone (TRA) to inhibit (3H)-serotonin intake in unipolar and bipolar endogenous depressed patients (women aged 17 to 57 years) was evaluated before and during the antidepressant treatment. The potency of IMI was lower and that of TRA higher in patients as compared to controls. The both drugs' potencies became normal in patients treated with antidepressants. The significant decrease of imipramine binding sites density (Bmax) was evident after the treatment as against the normal levels. Significant correlation was observed between a severity of the patient's state evaluated using Hamiltone depression rating scale and the TRA potency but not IMI potency or Bmax. The data suggest different mechanisms regulating the serotonin uptake sensitivity to IMI and TRA. These are apparently involved in the pathogenesis of endogenous depression.


Asunto(s)
Antidepresivos/uso terapéutico , Trastorno Bipolar/sangre , Plaquetas/metabolismo , Trastorno Depresivo/sangre , Imipramina/farmacología , Serotonina/sangre , Trazodona/farmacología , Adolescente , Adulto , Trastorno Bipolar/tratamiento farmacológico , Plaquetas/efectos de los fármacos , Medios de Cultivo , Trastorno Depresivo/tratamiento farmacológico , Interacciones Farmacológicas , Femenino , Humanos , Técnicas In Vitro , Persona de Mediana Edad , Antagonistas de la Serotonina , Tritio
11.
Kardiologiia ; 32(11-12): 10-2, 1992.
Artículo en Ruso | MEDLINE | ID: mdl-1297866

RESUMEN

To investigate if there can be alterations in the 5-hydroxytryptamine (5-HT) uptake system in the sensitivity of platelets in patients with essential hypertension, 38 hypertensive patients and 37 normotensive healthy subjects were compared. In patients, the maximal 5-HT uptake velocity was reduced. The density of binding sites for 3H-imipramine was elevated in hypertensive females, but unchanged in males. The sensitivity of 5-HT uptake to trazodone was unchanged in patients. Half-maximal concentrations of 5-HT for inducing a shape change reaction of platelets were positively correlated with diastolic blood pressure in male patients and were reduced in female mild hypertensives. It is suggested that these changes are likely to be involved in the pathogenesis of hypertension.


Asunto(s)
Plaquetas/metabolismo , Hipertensión/sangre , Receptores de Serotonina/metabolismo , Serotonina/metabolismo , Velocidad del Flujo Sanguíneo , Femenino , Humanos , Hipertensión/fisiopatología , Imipramina/farmacocinética , Masculino , Persona de Mediana Edad , Trazodona/farmacocinética
12.
Zh Nevrol Psikhiatr Im S S Korsakova ; 110(4 Suppl 2): 42-5, 2010.
Artículo en Ruso | MEDLINE | ID: mdl-20738025

RESUMEN

Platelet serotonin content in patients in the acute period of stroke is an important index of clinical changes during the post stroke period as well as a predictor of development of mental disorders. We studied the association between two polymorphisms (5-HTTLPR and Val66Met BDNF) and the platelet serotonin content in 47 patients with stroke. We also investigated the moderating effect of genetic variants on the association between platelet serotonin content and development of affective and anxiety disorders in stroke patients in the acute period of stroke. The interaction effect of two polymorphisms on levels of platelet serotonin was found. The lowest level was observed in patients with the diplotype LL*ValVal, the highest level--in the group of patients with the LL genotype and genotypes containing at least one copy of a Met allele. No moderating effect of genetic variants on the relationship between serotonin content and affective or anxiety disorder was found.


Asunto(s)
Plaquetas/metabolismo , Factor Neurotrófico Derivado del Encéfalo/genética , Proteínas de Transporte de Serotonina en la Membrana Plasmática/genética , Serotonina/metabolismo , Accidente Cerebrovascular/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Trastornos de Ansiedad/etiología , Trastornos de Ansiedad/metabolismo , Plaquetas/química , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trastornos del Humor/etiología , Trastornos del Humor/metabolismo , Polimorfismo Genético , Serotonina/análisis , Accidente Cerebrovascular/complicaciones
17.
Artículo en Ruso | MEDLINE | ID: mdl-20037570

RESUMEN

A comparative study of the platelet resistance to different effects was conducted in patients with chronic schizophrenia and healthy controls using column chromatography on sepharose CL-2B with the incubation at 5 degrees C during 18 h. This method allows to reveal the greater platelet activation in patients compared to the controls. The platelet number in platelet rich plasma (PRP) obtained by centrifugation was 1,8 times less in male patients with chronic schizophrenia than in the controls. This considerable decrease of platelet number in patients may be associated with the platelet deficiency in the blood stream and/or the destruction of activated platelets during blood sampling and centrifugation for the PRP preparation.


Asunto(s)
Plaquetas/fisiología , Activación Plaquetaria/fisiología , Esquizofrenia/sangre , Adulto , Cromatografía , Enfermedad Crónica , Cognición , Estudios de Seguimiento , Humanos , Masculino , Recuento de Plaquetas , Pronóstico , Esquizofrenia/fisiopatología , Índice de Severidad de la Enfermedad
18.
Artículo en Ruso | MEDLINE | ID: mdl-18379499

RESUMEN

A sample included 59 patients, 38 males and 21 females, mean age (M+/-SD) 33,4+/-10,2 years, age-at-onset 26+/-9,5 years, illness duration 7,8+/-6,1 years, with episodic progressive schizophrenia (ICD-10: schizophrenia, paranoid type, F20.0) with continuous course at the stage of exacerbation. Clinical symptoms were assessed using the PANSS. Platelet 5-HT content, 3H-serotonin uptake (Vmax), 3H-imipramine receptor density (Bmax), high- and low molecular weight human serotonin platelet transporter protein immunoreactivity (HMW-SERT and LMW-SERT values) were measured. The most frequent psychotic symptoms were delusions, conceptual disorganization and hallucinations, with the majority of patients experiencing from one to three symptoms. A significant increase of platelet 5-HT content and 3H-imipramine receptor density (Bmax) was found in male patients. In the male group, delusions, conceptual disorganization and hallucinations as well as PANSS psychotic cluster scores were correlated positively with 5-HT content and negatively with HMW-SERT and LMW-SERT values. Possible reasons of the differences in correlations of platelet 5-HT serotonin and serotonin transporter values with psychotic symptoms are discussed. The results are additional evidence for the involvement of serotonergic dysfunction in the pathogenesis of schizophrenic psychoses. They confirm the usefulness of testing of platelet 5-HT content and SERT immunoreactivity as biological markers of schizophrenic psychoses, in particular for male patents.


Asunto(s)
Plaquetas/metabolismo , Trastornos Psicóticos/sangre , Receptores de Droga/metabolismo , Receptores de Serotonina 5-HT3/metabolismo , Esquizofrenia Paranoide/complicaciones , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo , Serotonina/metabolismo , Adolescente , Adulto , Anciano , Biomarcadores , Femenino , Citometría de Flujo , Humanos , Imipramina , Immunoblotting , Masculino , Persona de Mediana Edad , Prevalencia , Pronóstico , Trastornos Psicóticos/complicaciones , Trastornos Psicóticos/epidemiología , Esquizofrenia Paranoide/sangre , Índice de Severidad de la Enfermedad , Factores Sexuales
19.
Artículo en Ruso | MEDLINE | ID: mdl-15822741

RESUMEN

Using scanning electronic microscopy of peripheral blood platelets in 32 patients with amyotrophic lateral sclerosis (ALS) and 6 patients with multiple sclerosis (MS), platelets activation, emerging in pseudopodiums formation, aggregation and lysis, was found. Platelets activation was more pronounced in ALS than in MS. It was most markedly seen for quantitative evaluation of the above traits. The features of platelet activation found in the study support the evidence for considering ALS as a systemic disorder being characterized by a broad spectrum of alterations of biological processes.


Asunto(s)
Esclerosis Amiotrófica Lateral/sangre , Plaquetas/ultraestructura , Esclerosis Múltiple/sangre , Plaquetas/fisiología , Interpretación Estadística de Datos , Humanos , Microscopía Electrónica de Rastreo , Agregación Plaquetaria , Propiedades de Superficie
20.
Artículo en Ruso | MEDLINE | ID: mdl-15825226

RESUMEN

Fifty-nine patients, 21 women and 38 men, with ICD-10 diagnosis of schizophrenia (F20.0), attack-like type, were treated with olanzapine during 28 weeks (8-weeks of acute and 20-weeks of maintenance therapy). Evaluation of clinical symptoms measured by the Positive and Negative Syndromes scale (PANSS) revealed that female patients responded better to therapy as compared to male ones, with PANSS total, PANSS negative and PANSS general psychopathological scores being significantly reduced (p < 0.006) in females after 1 week of the treatment and in males--after 2 weeks. In the female group, a reduction of PANSS total score by 50% in the acute stage of treatment qualified as a very good response was observed in 7 (33%) patients and in the male group--in 1 (2.7%). The between-groups difference was highly significant (p = 0.002). When examined for a rate of 3H-serotonin uptake into platelets, density of sites of 3H-imipramine binding on the whole platelets, platelet serotonin level and levels of high- also low-molecular weight forms of platelet immunoreactive serotonin transporter protein, a significant decrease of the platelet serotonin level, comparing to controls, was detected in the female group before treatment. During the treatment, this parameter gradually increased up to control level. Other parameters did not change significantly for 28-weeks of therapy and did not differ from the control values. There were positive correlations between the levels of platelet serotonin before treatment and subsequent reduction of the PANSS total and positive subscale scores in the female group. In responders with a very good treatment-related response, the serotonin level in the platelets before treatment was higher compared to the values in resistant patients: 5.4 +/- 2.5 and 2.7 +/- 1.3 nmol/10(9) cells, respectively. Relative risk (RR) of unfavorable treatment outcome in patients with initially reduced levels of platelet serotonin was approximately twice lower (RR = 1.83; Cl 95% 1.1-34.9) than that in patients with normal or elevated levels of platelet serotonin. The results suggest that selection of patients with initial higher level of platelet serotonin before olanzapine treatment can reduce the risk of non-responding to therapy by 36%.


Asunto(s)
Antipsicóticos/uso terapéutico , Benzodiazepinas/uso terapéutico , Plaquetas/metabolismo , Esquizofrenia/sangre , Esquizofrenia/tratamiento farmacológico , Inhibidores Selectivos de la Recaptación de Serotonina/uso terapéutico , Serotonina/metabolismo , Adulto , Factores de Edad , Antipsicóticos/administración & dosificación , Benzodiazepinas/administración & dosificación , Interpretación Estadística de Datos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Olanzapina , Esquizofrenia/diagnóstico , Serotonina/sangre , Inhibidores Selectivos de la Recaptación de Serotonina/administración & dosificación , Factores Sexuales , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA